Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (NASDAQ: TOI) is a leading cancer treatment and research organization focused on providing high-quality, value-based oncology care. Founded in 2007, TOI has established itself as a premier provider of comprehensive cancer treatment with over 70 clinic locations and a team exceeding 110 clinicians. The Institute offers a wide range of services, including infusion centers, outpatient blood transfusions, stem cell transplants, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling.
TOI operates in three primary segments: dispensary services, patient services, and clinical trials. The core of its operations lies in patient services, where personalized care plans are developed in collaboration with patients and their families to meet their unique needs. TOI’s mission is to advance oncology by making cutting-edge, evidence-based cancer care accessible within the community setting.
In recent developments, TOI announced a strategic partnership with WellBe Senior Medical to extend its High-Value Cancer Care Program to eligible patients in Illinois and Ohio. This initiative aims to enhance patient satisfaction, reduce acute care facility utilization, and support patients throughout their cancer treatment journey. Furthermore, TOI has joined Carrum Health’s Centers of Excellence network, providing high-value oncology care to non-metastatic breast cancer patients in Las Vegas.
TOI’s commitment to innovation in oncology care is also highlighted through its strategic collaboration with Healthly, a growing healthcare company focused on preventive medicine. Starting July 2024, TOI will offer its specialized cancer care services to Healthly’s affiliated patients and physicians across Southern California. This collaboration underscores TOI’s dedication to providing accessible and comprehensive cancer care in community settings.
Financially, TOI has a strong foundation supported by revenue generated predominantly from patient services. The Institute continues to expand its influence through partnerships and value-based care agreements, ensuring a sustainable and impactful presence in the oncology landscape. For more information, please visit theoncologyinstitute.com.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has announced the promotions of Dr. Daniel Virnich to President and Dr. Matt Miller to Chief Operating Officer, effective March 15, 2022. These changes are part of a response to TOI's rapid growth. Dr. Virnich, who joined in 2020, will oversee various functions including Operations and Compliance, while Dr. Miller will manage all field and central operations nationally. Both leaders have previously driven tangible improvements in operational efficiency and patient satisfaction, positioning TOI for continued development in specialized oncology care.
The Oncology Institute (TOI) has established a value-based agreement with MaxHealth to deliver medical oncology care in Pinellas and Hillsborough Counties, beginning March 1, 2022. This partnership aims to enhance patient care through TOI's innovative oncology model, which includes over 170 clinical trials and comprehensive oncology services. The initiative targets expansion into neighboring counties, reflecting TOI's commitment to improving cancer care accessibility. Both organizations emphasize a shared goal of personalized patient care and satisfaction.
The Oncology Institute of Hope and Innovation (TOI) has entered a value-based agreement with MaxHealth to provide medical oncology care in Pinellas and Hillsborough Counties, Florida. This partnership, effective from March 1, 2022, aims to enhance cancer care access and quality through community-focused services, including clinical trials and stem cell transplants. TOI plans to expand this initiative to neighboring counties shortly. Both organizations emphasize a commitment to personalized care and improving patient satisfaction.
The Oncology Institute (TOI) will release its fourth quarter and full year results on March 10, 2022, after market close. Following the results, a conference call is scheduled for 5:00 p.m. ET, accessible via phone or webcast. TOI specializes in delivering advanced, value-based cancer care to over 1.5 million patients, with 54 clinic locations and a team of 80+ clinicians. Their services include clinical trials, stem cell transplants, and transfusions. Interested parties can join the call and access a replay through the provided contact information.
The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has expanded its footprint by opening its 54th clinic in Lakeland, Florida, enhancing oncology services available in Polk County. This new clinic, which is the sixth in Florida, aims to provide patients with convenient access to oral chemotherapeutics and blood transfusion services. With experienced providers onboard, the institute continues to showcase its commitment to value-based cancer care. The expansion aligns with TOI's efforts to elevate healthcare standards and meet growing patient needs in the region.
TOI has expanded its physician network by acquiring the practices of Dr. Ellsworth R. Grant and Dr. Leo E. Orr, adding to its team of over 80 clinicians. This acquisition will enhance TOI's ability to provide value-based oncology care to more than 1.5 million patients across its locations.
The new facility in Westlake offers advanced medical services similar to other TOI clinics, enhancing patient access to high-quality cancer care.
The Oncology Institute (TOI) has successfully completed its business combination with DFP Healthcare Acquisitions Corp., with approval received on November 12, 2021.
This merger, now valued at $842 million, enables TOI to retain approximately $133 million for growth initiatives. TOI’s stock began trading on NASDAQ under the symbols 'TOI' and 'TOIIW'. With a history of providing high-quality cancer care to over 150,000 patients across four states, TOI aims to disrupt the $200 billion U.S. oncology market through a value-based care model.
The Oncology Institute (NASDAQ: TOI) has completed its fourth acquisition in Q4 by acquiring the practice of Dr. Honghao Yang and his two oncology clinics in California. This expands TOI's coverage in the San Gabriel Valley, complementing its existing locations. Dr. Yang has over 30 years of experience and is recognized for his patient care approach. The new clinics will have multilingual staff to serve diverse communities. TOI aims to enhance its operational capacity and patient services through this integration.
The Oncology Institute (TOI) has successfully completed its merger with DFP Healthcare Acquisitions Corp., with the transaction approved on November 12, 2021. This merger establishes TOI as a public company, trading under the new ticker symbols 'TOI' and 'TOIIW' on NASDAQ. The transaction values TOI at $842 million, with a significant cash infusion of approximately $334 million, including $275 million from a private placement. The funds will support expansion initiatives across multiple states, driving TOI's value-based oncology care strategy.
FAQ
What is the current stock price of The Oncology Institute (TOI)?
What is the market cap of The Oncology Institute (TOI)?
What services does The Oncology Institute, Inc. provide?
Where are The Oncology Institute's clinics located?
What recent partnerships has TOI announced?
How does TOI contribute to cancer research?
What is the focus of TOI's value-based care model?
How can patients access TOI's services?
What makes TOI's High-Value Cancer Care Program unique?
Who are the primary beneficiaries of TOI's services?
What role do clinical trials play at TOI?
How does TOI support patients financially?
